NCT07480863 2026-03-18
Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZL
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT07448324 2026-03-04
Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06583837 2026-02-27
Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lymphoma
Fudan University
Phase 2 Active not recruiting
NCT07247383 2025-11-25
Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Active not recruiting
NCT07208981 2025-10-06
Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06700798 2025-06-17
Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial
The First Affiliated Hospital of Nanchang University
Phase 2 Recruiting
NCT06793189 2025-01-27
MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
Ruijin Hospital
Phase 2 Not yet recruiting
NCT06566807 2024-08-22
Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma
Huai'an First People's Hospital
Phase 2 Recruiting
NCT06513234 2024-07-22
Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT06454968 2024-06-18
Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.
Peking Union Medical College Hospital
Phase 2 Recruiting